These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11508155)

  • 41. Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease.
    Nesher G; Nesher R; Mates M; Sonnenblick M; Breuer GS
    Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S30-4. PubMed ID: 18799050
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of pulse corticosteroid therapy for juvenile dermatomyositis.
    Paller AS
    Pediatr Dermatol; 1996; 13(4):347-8. PubMed ID: 8844758
    [No Abstract]   [Full Text] [Related]  

  • 43. Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss.
    Cacoub P; Chemlal K; Khalifa P; Wechsler B; De Gennes C; Belmatoug N; Cohen P; Ziza JM; Verdoncq B; Piette JC
    J Rheumatol; 2001 Nov; 28(11):2474-9. PubMed ID: 11708421
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Disulon in the treatment of Horton's disease. Experience with 20 patients].
    Liozon F; Vidal E; Bonnetblanc JM; Michel JP; Weinbreck P; Bordessoule D; Loustaud V
    Ann Med Interne (Paris); 1986; 137(4):299-306. PubMed ID: 3777739
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision.
    Liu GT; Glaser JS; Schatz NJ; Smith JL
    Ophthalmology; 1994 Nov; 101(11):1779-85. PubMed ID: 7800356
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Development of Horton's disease under corticotherapy].
    Graisely B; Audebert AA; Offret H; de Saint-Maur PP
    Nouv Presse Med; 1980 Oct; 9(37):2736. PubMed ID: 7433074
    [No Abstract]   [Full Text] [Related]  

  • 47. Steroid-sparing effect and toxicity of dapsone treatment in giant cell arteritis: A single-center, retrospective study of 70 patients.
    Ly KH; Dalmay F; Gondran G; Palat S; Bezanahary H; Cypierre A; Fauchais AL; Liozon E
    Medicine (Baltimore); 2016 Oct; 95(42):e4974. PubMed ID: 27759628
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Role of dapsone in the treatment of Horton's disease and polymyalgia rheumatica].
    Doury P; Fabresse FX; Pattin S; Eulry F; Celton H; Larroque P
    Ann Med Interne (Paris); 1984; 135(1):31-5. PubMed ID: 6703568
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epidural thoracic lipomatosis induced by long-term steroid treatment case illustration.
    Pinsker MO; Kinzel D; Lumenta CB
    Acta Neurochir (Wien); 1998; 140(9):991-2. PubMed ID: 9842440
    [No Abstract]   [Full Text] [Related]  

  • 50. [Unusual manifestation of Horton's disease: apropos of 2 case reports].
    Boschi A; Vliers S; Lefebvre C
    Bull Soc Belge Ophtalmol; 1995; 259():189-95. PubMed ID: 8983534
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The bane of giant cell arteritis from an ophthalmological viewpoint].
    Meli B; Landau K; Gloor BP
    Schweiz Med Wochenschr; 1996 Oct; 126(43):1821-8. PubMed ID: 9005521
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study.
    Hunder GG; Sheps SG; Allen GL; Joyce JW
    Ann Intern Med; 1975 May; 82(5):613-8. PubMed ID: 1137255
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Horton's disease and rhizomelic pseudopolyarthritis. Developmental data apropos of 95 cases].
    Piton JL; Zagala A; Rebuffet JL; Reynes O; Reynes JF; Souteyrand P; Phelip X
    Rev Rhum Mal Osteoartic; 1987 Jan; 54(1):7-13. PubMed ID: 3563372
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Duration of corticosteroid therapy in giant cell arteritis.
    Fernandez-Herlihy L
    J Rheumatol; 1980; 7(3):361-4. PubMed ID: 6772784
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Treatment of giant cell arteritis].
    Sailler L; Pugnet G; Bienvenu B
    Rev Med Interne; 2013 Jul; 34(7):431-7. PubMed ID: 23562185
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Iatrogenic morbidity accompanying suppression of temporal arteritis by adrenal corticosteroids.
    Rubinow A; Brandt KD; Cohen AS; Sack B
    Ann Ophthalmol; 1984 Mar; 16(3):258-60, 262, 264-5. PubMed ID: 6712068
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Osteopenia in patients with glomerular diseases requiring long-term corticosteroid therapy.
    de Deus RB; Ferreira AC; Kirsztajn GM; Heilberg IP
    Nephron Clin Pract; 2003; 94(3):c69-74. PubMed ID: 12902633
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polymyalgia rheumatica and giant cell arteritis. The dilemma of therapy.
    Wilske KR; Healey LA
    Postgrad Med; 1985 Jun; 77(8):243-8. PubMed ID: 4001042
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis.
    Salvarani C; Boiardi L; Macchioni P; Rossi F; Tartoni P; Casadei Maldini M; Mancini R; Beltrandi E; Portioli I
    Ann Rheum Dis; 1995 Aug; 54(8):640-4. PubMed ID: 7677440
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [A case of temporal arteritis presenting with sensorineural hearing loss].
    Amoroso C; Vindigni MR; Aimoni C
    Recenti Prog Med; 2001 Dec; 92(12):751-3. PubMed ID: 11822096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.